Association of BMP-14 rs143383 polymorphism with its susceptibility to osteoarthritis
A meta-analysis and systematic review according to PRISMA guideline
Yi Yin, PhD, Yan Wang, PhD

Abstract
Background: Osteoarthritis (OA) is a complex disease which can be caused by both environmental and genetic factors. A functional locus rs143383 of bone morphogenetic protein-14 (BMP-14) has been pointed out to be associated with OA etiology, but conflicting conclusions have been reached. To provide a more comprehensive conclusion about this issue, we performed this meta-analysis.

Methods: Relevant studies were searched from electronic databases including PubMed, Chinese National Knowledge Infrastructure, Embase, and Wanfang. The strength of correlations was examined with pooled odds ratios (ORs) and 95% confidence intervals (95% CIs). Subgroup analyses stratified by ethnicity and source of control were carried out. All statistical analyses were performed with STATA software (version 12.0).

Results: Overall, BMP-14 rs143383 polymorphism was negatively correlated with the susceptibility to knee OA and hand OA under genetic contrasts of CC versus TT, CC+TC versus TT, CC versus TT+TC, C versus T, TC versus TT (OR =0.71, 95% CI = 0.65–0.79; OR =0.81, 95% CI =0.73–0.89; OR =0.79, 95% CI =0.71–0.86; OR =0.85, 95% CI =0.81–0.90; OR =0.84, 95% CI = 0.75–0.93), and TC versus TT, CC versus TT+TC, C versus T (OR =0.76, 95% CI =0.68–0.89; OR =0.79, 95% CI =0.68–0.92; OR =0.90, 95% CI =0.85–0.95), respectively; similar results were observed in subgroups after stratification analyses. Additionally, the polymorphism also reduced hip OA risk in Asian group after stratified analysis by ethnicity.

Conclusion: BMP-14 rs143383 polymorphism may be a protective factor against OA occurrence.

Abbreviations: 95%CI = 95% confidence interval, BMP-14 = bone morphogenetic protein-14, GDF5 = growth and differentiation factor-5, NOS = Newcastle–Ottawa Scale, OA = osteoarthritis, OR = odds ratio.

Keywords: BMP-14, meta-analysis, osteoarthritis, polymorphism

1. Introduction
Osteoarthritis (OA), also called degenerative joint disease or degenerative arthritis, is the most common form of arthritis, with knee and hip OA affecting approximately 3.8% of the world population as of 2010.[1–3] The characteristics of OA include not only damage and gradual loss of articular cartilage, but also weakened periarticular muscles, osteophyte formation, ligament laxity, deformed subarticular bone as well as synovial inflammation.[4] When the synthesis and degradation of articular cartilage become imbalanced, the cartilage will be worn away and destructed, thus leading to OA; so, OA is a chronic degenerative noninflammatory disorder.[3] It has been reported that among people over 60 years old, about 10% of men and 18% of women suffer from this disease.[5] Aging, hormonal, environmental, and hereditary factors have all been demonstrated to be involved in the occurrence and progression of this disease, and 35% of knee OA cases are caused by genetic components.[3,7–9]

Bone morphogenetic protein-14 (BMP-14), also known as growth and differentiation factor-5 (GDF5), is one of the most frequently studied targets for OA onset.[10,11] Belonging to the transforming growth factor-β family, it is closely associated with BMPs[12] and affects the development, maintenance, and repair of cartilage, bone, and other tissues of synovial joint.[13–17] BMP-14 is involved in chondrogenesis and joint formation, and mutations in its coding gene can lead to diseases, for example, chondrodysplasias.[18] Studies on transgenic mice also show that BMP-14 can regulate the formation, growth, and differentiation of the skeletal elements.[19–21] Additionally, BMP-14 expresses in adult articular cartilage and stimulates the synthesis of proteoglycan in articular cartilage explants.[22] All these evidences show that the susceptibility to OA may be affected by BMP-14 expression. The polymorphism rs143383 in the 5′-untranslated region of BMP-14 gene has been suggested to modulate the transcriptional activity of the gene, thus being involved in the pathogenesis of OA.[23] The association between BMP-14 rs143383 polymorphism and OA risk has been investigated in previous studies,[23–36] but
their conclusions were inconsistent. For example, Miyamoto et al.\cite{23} reported that BMP-14 rs143383 polymorphism was significantly associated with knee OA in Japanese and Han Chinese. However, a study from Tsezou et al.\cite{31} supported that rs143383 polymorphism was not related to knee OA in Greek Caucasians. In view of the conflicting results, we retrieved all eligible studies from online databases and undertook present meta-analysis to further explore the role of BMP-14 rs143383 polymorphism in OA risk.

2. Materials and methods

This meta-analysis was undertook in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.

2.1. Search strategy

A systematic search of available studies published between 2007 and 2013 on the relationship between BMP-14 rs143383 polymorphism and the risk of OA was performed in the databases of PubMed, Embase, Medline, Google Scholar, Wanfang, and Chinese National Knowledge Infrastructure. Primary search words included: “osteoarthritis” or “OA,” “BMP-14” or “GDF5” or “growth differentiation factor 5,” and “polymorphism” or “variant” or “single nucleotide polymorphism” or “SNP.” For instance, we adopted “osteoarthritis,” “GDF5,” and “polymorphism” to search relevant articles in PubMed. Both medical subject heading and nonmedical subject heading terms were applied in the searching process to obtain as many relevant papers as possible. Searching language was restricted to English and Chinese. Additional studies were obtained through examining references.

2.2. Inclusion and exclusion criteria

The following inclusion criteria were set for eligible studies: original study evaluating the role of BMP-14 rs143383 polymorphism in OA occurrence; with both cases and controls; providing sufficient genetic data for calculating odds ratios (ORs) and 95% confidence intervals (95% CIs); and focusing on humans. Exclusion criteria included: animal studies; without original data; insufficient genotype information; and reviews, comments, abstracts, or studies not in English and Chinese.

2.3. Data extraction

Two investigators undertook data extraction according to a standardized form. Essential information was extracted from all qualified studies, including first author’s name, publication year, country, ethnicity, source of control, method for genotyping, the number of participants, distribution of genotypes and alleles, and \(P\) value for Hardy–Weinberg equilibrium in control group. Any inconsistent opinion was resolved through discussion to reach unanimity. Studies with different ethnic groups were regarded as individual studies for our analysis.

2.4. Quality assessment

Quality of eligible studies were independently assessed by 2 investigators based on Newcastle–Ottawa Scale (NOS) which included 3 aspects: selection, comparability and exposure, and each satisfactory answer received 1 point. Studies with a score equal to or higher than 6 were identified as of high quality, 4 to 5 scores indicated a modulate quality.

2.5. Statistical analysis

The strength of correlations between BMP-14 rs143383 polymorphism and OA risk was estimated with pooled ORs and 95% CIs. \(\chi^2\) test was applied to determine whether the observed genotype frequencies in the control group accorded with Hardy–Weinberg Equilibrium. The significance of the summary OR was assessed by Z test. Subgroup analyses were carried out based on ethnicity and control source. Heterogeneity among studies was detected by \(\chi^2\)-based Q-statistic test. When \(P\) value was less than .05 in Q test which indicated significant heterogeneity, the random-effects model was used for OR calculation; otherwise, the fixed-effects model was applied. In addition, sensitivity analysis was performed by individually omitting each single study to assess the stability of our results. Furthermore, the possible publication bias was detected with Begg funnel plot and Egger tests. STATA software (version 12.0) was applied for statistical analyses. For all tests, \(P < .05\) was considered to represent statistical significance.

3. Results

3.1. Study characteristics

Figure 1 describes the selection process for eligible studies. Altogether 114 articles were initially retrieved through the database search. Among them, 47 papers were firstly deleted for irrelevant studies (26), concerning prognosis or treatment response (13), and not human studies (8). Then 37 more publications were removed from the remaining 67 papers due to not involving BMP-14 gene (16) and OA (21). However, after full-text assessment, another 16 records were further excluded for not detecting BMP-14 rs143383 polymorphism (9), republished data (3), and case-only studies (4). Therefore, altogether 14 eligible articles covering 53,510 participants (19,973 cases and 33,537 controls) were included in the present study.\cite{23–36} A total of 38 independent studies published between 2007 and 2013 were incorporated finally. Thereinto, 21 studies focused on knee OA; 9 studies referred to hip OA; and 8 studies were implicated in hand OA. Table 1 displays the characteristics of all eligible studies. Two included studies\cite{33,34} were found the relative poor quality through NOS assessment, and the rest studies had the moderate and good quality in this meta-analysis.

3.2. Quantitative synthesis

As shown in Table 2, the pooled ORs indicated that BMP-14 rs143383 polymorphism decreased the risk of knee OA and hand OA under CC versus TT, CC + TC versus TT, CC versus TT + TC, C versus T, TC versus TT (OR = 0.71, 95% CI = 0.65–0.79 [Fig. 2]; OR = 0.81, 95% CI = 0.73–0.89; OR = 0.79, 95% CI = 0.71–0.86; OR = 0.85, 95% CI = 0.81–0.90; OR = 0.84, 95% CI = 0.75–0.93) and CC versus TT, CC versus TT + TC, C versus T (OR = 0.76, 95% CI = 0.65–0.89 [Fig. 3]; OR = 0.79, 95% CI = 0.68–0.92; OR = 0.90, 95% CI = 0.85–0.95) genetic models, respectively. Furthermore, a similar trend was observed in Asian (Fig. 2), Caucasian (Fig. 2), hospital-based, population-based, and other-source subgroups after for knee OA after stratified analyses by ethnicity and source of control, as well as in
population-based group (Fig. 3) for hand OA after stratified analysis by source of control.

As for the risk of hip OA, the polymorphism rs143383 showed no significant correlation in total analysis, but expressed a decreasing effect in Asian group under all 5 genetic comparisons after stratified analysis by ethnicity.

3.3. Heterogeneity test

Q test revealed significant heterogeneity for hip OA under all 5 contrasts, so the random-effects model was chosen for calculating ORs. As for knee OA and hand OA, the use of random- or fixed-effects model was determined according to the principle above mentioned. As regards the source of significant heterogeneity, we found that after stratified analysis by ethnicity and source of control, the degree of the significance was alleviated or even eliminated in some subgroups, suggesting the possible origins of heterogeneity might contain but not limit to ethnicity and source of control.

3.4. Sensitivity analysis

Sensitivity analysis was carried out to reflect the influence of each dataset on the summary ORs by deleting each single study included in the meta-analysis one by one. No material change was observed in corresponding pooled ORs, which suggested that our overall results were stable and robust.

3.5. Publication bias

The possible publication bias was assessed with Begg funnel plot and Egger test. Funnel plot seemed symmetrical (Fig. 4), which was also supported by P value of Egger test (P = .056). Therefore, no significant publication bias existed in the present study.

4. Discussion

OA, a multifactorial disease, affects about 5% of people aged over 45 years old, and causes substantial morbidity and disability, particularly among the elderly, leading to a severe health care burden in developed countries. In addition to the degradation of articular cartilage and subchondral bone deformity, OA also can result in a series of other symptoms like joint pain and stiffness; so, OA patients may fail to perform normal daily activities. As yet, OA still can not be completely cured, and the effects of existing treatments are mainly on relieving pains and on enhancing the functions of affected joints. Therefore, it is crucial important to understand the pathology of the disease so as to facilitate the finding of prevention strategies and/or more effective treatments. Many genes have been reported to be associated with OA susceptibility, including BMP-14. The protein encoded by BMP-14 can regulate chondrogenesis, and the deficiencies of this gene may cause joint development anomaly. BMP-14 rs143383 polymorphism has been identified to be linked to BMP-14 expression, and its relationship with the susceptibility to OA has become a hot topic of studies on this issue, but their findings were far from uniform.

In the present meta-analysis, we systematically assessed the contribution of BMP-14 rs143383 polymorphism to the risk of OA based on 19973 cases and 33537 controls, and found that the SNP reduced the susceptibility to knee OA and hand OA not only in total analysis but also in subgroup analysis. Meanwhile, the polymorphism also exerted a similar effect on hip OA risk in Asian group, thought its association with the disease had no statistical significance in total analysis. Generally, the C allele of this polymorphism played a protective role against the risk of OA.

The association of BMP-14 rs143383 polymorphism with OA risk has been extensively explored in previous studies, but the results are controversial. For example, Tawonsawatruk et al investigated the association of BMP-14 rs143383 polymorphism with the risk of knee OA in Thai population, and found that the TT genotype enhanced the risk of knee OA compared to the CC genotype, showing that the T allele was significantly correlated with increased susceptibility to knee OA. In the study by Mishra et al., the TT genotype was also found to be more frequent in case group than in control group, thus suggesting the genotype...
## Table 1
Major characteristics of all studies incorporated in the meta-analysis.

| First author | Publication year | Country          | Ethnicity | Control source | Genotyping method                                                                 | Sample size | T  | C  | HWE  | NOS |
|--------------|------------------|------------------|-----------|----------------|------------------------------------------------------------------------------------|-------------|----|----|------|-----|
| Knee OA      |                   |                  |           |                |                                                                                     |              |    |    |      |     |
| Tawonsawatruk| 2011              | Thailand         | Asian     | HB             | PCR-RFLP                                                                           | 90          | 103| 117| 63   | 93  |
| Chapman      | 2008              | UK               | Caucasian | PB             | Mass spectrometry                                                                  | 142         | 724| 180| 909  | 104 |
| Tseou        | 2007              | Greece           | Caucasian | HB             | Direct sequence                                                                    | 251         | 268| 316| 186  | 213 |
| Southam      | 2007              | Spain            | Caucasian | HB             | TaqMan                                                                             | 274         | 1196| 340| 208  | 951 |
| Southam      | 2007              | UK               | Caucasian | HB             | PCR-RFLP                                                                           | 349         | 822| 450| 248  | 624 |
| Mishra       | 2013              | India            | Asian     | HB             | PCR-RFLP                                                                           | 300         | 300| 378| 222  | 272 |
| Valdes       | 2009              | UK               | Caucasian | PB             | Allele-specific PCR                                                                | 259         | 509| 350| 168  | 412 |
| Valdes       | 2009              | Netherlands      | Caucasian | HB             | Allele-specific PCR                                                                | 735         | 646| 987| 483  | 487 |
| Cao          | 2010              | Korea            | Asian     | PB             | PCR-RFLP                                                                           | 276         | 208| 415| 137  | 165 |
| Miyamoto     | 2007              | Japan            | Asian     | HB             | TaqMan, Invader, DNA fragment analysis, or direct sequence                        | 313         | 485| 491| 135  | 289 |
| Valdes       | 2009              | Japan            | Asian     | PB             | TaqMan, Invader, DNA fragment analysis, or direct sequence                        | 718         | 861| 1131| 305  | 446 |
| Valdes       | 2009              | Netherlands      | Caucasian | PB             | Allele-specific PCR                                                                | 667         | 2097| 353| 221  | 2136|
| Valdes       | 2009              | Netherlands      | Caucasian | PB             | Allele-specific PCR                                                                | 725         | 1737| 1069| 381  | 901 |
| Takahashi    | 2010              | Japan            | Asian     | HB-PB          | TaqMan, Invader, DNA fragment analysis, or direct sequence                        | 393         | 1225| 1445| 421  | 621 |
| Valdes       | 2011              | UK               | Caucasian | PB             | Allele-specific PCR                                                                | 1141        | 536| 1445| 837  | 397 |
| Valdes       | 2011              | UK               | Caucasian | PB             | Allele-specific PCR                                                                | 867         | 758| 1187| 547  | 574 |
| Valdes       | 2011              | UK               | Caucasian | PB             | Allele-specific PCR                                                                | 65          | 427| 88  | 42   | 339 |
| Valdes       | 2011              | UK               | Caucasian | PB             | TaqMan                                                                             | 151         | 1582| 195 | 107  | 134 |
| Evangelou    | 2009              | Iceland          | Caucasian | PB             | Centaurus platform                                                                 | 1071        | 1169| 1471| 671  | 755 |
| Evangelou    | 2009              | UK               | Caucasian | Family-based   | Illumina platform                                                                  | 177         | 548| 230| 124  | 417 |
| Evangelou    | 2009              | Finland          | Caucasian | Family-based   | Mass spectrometry                                                                  | 109         | 209| 124| 94   | 167 |
| Hip OA       |                   |                  |           |                |                                                                                     |              |    |    |      |     |
| Vaes         | 2009              | Netherlands      | Caucasian | PB             | TaqMan                                                                             | 287         | 2757| 353| 221  | 2136|
| Chapman      | 2008              | UK               | Caucasian | PB             | Mass spectrometry                                                                  | 106         | 724| 136| 76   | 539 |
| Valdes       | 2009              | UK               | Caucasian | PB             | Allele-specific PCR                                                                | 787         | 646| 1029| 545  | 487 |
| Valdes       | 2009              | UK               | Caucasian | PB             | Allele-specific PCR                                                                | 77          | 309| 91  | 63   | 412 |
| Southam      | 2007              | Spain            | Caucasian | HB             | PCR-RFLP                                                                           | 1221        | 922| 1165| 877  | 624 |
| Southam      | 2007              | UK               | Caucasian | HB             | TaqMan                                                                             | 304         | 1196| 361| 247  | 961 |
| Miyamoto     | 2007              | Japan            | Asian     | HB             | TaqMan, Invader, DNA fragment analysis, or direct sequence                        | 998         | 383| 1668| 328  | 511 |
| Evangelou    | 2009              | UK               | Caucasian | Family-based   | Illumina platform                                                                  | 51          | 561| 72  | 30   | 431 |
| Evangelou    | 2009              | Iceland          | Caucasian | PB             | Centaurus platform                                                                 | 1724        | 1169| 2353| 1095 | 755 |
| Hand OA      |                   |                  |           |                |                                                                                     |              |    |    |      |     |
| Vaes         | 2009              | Netherlands      | Caucasian | PB             | TaqMan                                                                             | 870         | 2180| 1125| 615  | 1739|
| Chapman      | 2008              | UK               | Caucasian | PB             | Mass spectrometry                                                                  | 515         | 1644| 692 | 338  | 624 |
| Chapman      | 2008              | UK               | Caucasian | PB             | Mass spectrometry                                                                  | 200         | 724| 239| 161  | 539 |
| Southam      | 2007              | UK               | Caucasian | HB             | TaqMan                                                                             | 240         | 1196| 301| 179  | 951 |
| Bijsterbosch | 2013              | --               | Caucasian | PB             | Mass spectrometry                                                                  | 248         | 725| 303| 193  | 540 |
| Evangelou    | 2009              | UK               | Caucasian | Family-based   | Illumina platform                                                                  | 140         | 645| 193| 91   | 496 |
| Evangelou    | 2009              | Iceland          | Caucasian | PB             | Centaurus platform                                                                 | 2510        | 1169| 3474| 1546 | 755 |
| Evangelou    | 2009              | Finland          | Caucasian | Family-based   | Mass spectrometry                                                                  | 82          | 209| 96  | 68   | 167 |

HB = hospital-based, HWE = Hardy–Weinberg equilibrium, NOS = Newcastle–Ottawa scale, OA = osteoarthritis, PB = population-based.
Table 2

BMP-14 rs143383 polymorphism and OA risk.

| OA location | Group/subgroup | CC vs TT | CC + TC vs TT | CC vs TT + TC | C vs T | TC vs TT |
|-------------|----------------|----------|---------------|---------------|--------|----------|
| Knee OA     | Asian          | 0.65 (0.54–0.78) | 0.77 (0.65–0.93) | 0.80 (0.67–0.95) | 0.85 (0.74–0.96) | 0.81 (0.67–0.98) |
|             | Caucasian      | 0.74 (0.66–0.84) | 0.82 (0.73–0.92) | 0.87 (0.82–0.95) | 0.85 (0.74–0.98) |
|             | Other-source   | 0.74 (0.65–0.85) | 0.85 (0.72–0.98) | 0.81 (0.71–0.92) | 0.81 (0.71–0.93) |
|             | Total          | 0.71 (0.65–0.78) | 0.81 (0.73–0.89) | 0.79 (0.71–0.86) | 0.81 (0.73–0.89) | 0.84 (0.75–0.93) |
| Model for heterogeneity | Fixed | 0.65 (0.54–0.78) | 0.77 (0.65–0.93) | 0.80 (0.67–0.95) | 0.85 (0.74–0.96) | 0.81 (0.67–0.98) |

| Hip OA      | Caucasian      | 0.91 (0.78–1.06) | 0.92 (0.81–1.05) | 0.96 (0.82–1.12) | 0.95 (0.89–1.01) | 0.92 (0.77–1.10) |
|             | Other-source   | –             | –             | –             | –             | –             |
|             | Total          | 0.81 (0.61–1.07) | 0.84 (0.67–1.05) | 0.88 (0.68–1.13) | 0.88 (0.76–1.01) | 0.84 (0.66–1.06) |

| Hand OA     | PB             | 0.74 (0.62–0.88) | 0.79 (0.75–1.32) | 0.81 (0.65–0.96) | 0.82 (0.62–1.04) | 0.90 (0.54–1.49) |
|             | Other-source   | –             | –             | –             | –             | –             |
|             | Total          | 0.76 (0.65–0.88) | 0.79 (0.76–1.32) | 0.79 (0.68–0.92) | 0.80 (0.65–0.95) | 1.00 (0.79–1.27) |

TT, wild homozygous genotype; TC, heterozygous genotype; CC, mutant homozygous genotype. HB = hospital-based, OA = osteoarthritis, PB = population-based.

Figure 2. Forest plot for the association between BMP-14 rs143383 polymorphism and knee OA risk under CC versus TT genetic model. OA = osteoarthritis, BMP-14 = bone morphogenetic protein-14.
was as a risk factor for knee OA. However, no apparent relationship between rs143383 polymorphism and knee OA risk was detected by Tsezou et al in Greek population.[31] Focusing on hand OA risk, Evangelou et al[33] revealed that the SNP was also significantly related to the susceptibility to hand OA. Moreover, the C allele of BMP-14 rs143383 polymorphism was manifested to reduce the risk of hip OA in female carriers.[35] Nevertheless, Chapman et al[28] revealed no obvious effects of the SNP on the susceptibility to either hand OA or hip OA.

The inconsistent results may be explained by the following aspects: the studied population varied in terms of ethnicity, age, gender, and lifestyle; restricted number of cases and controls might affect the study results; different criteria were used for selecting study participants; and interfering factors were not adjusted in all studies.

Since the present study included altogether 19973 cases and 33537 controls, our results were statistically more powerful than results in any single study. Nevertheless, some limitations of the present study should be addressed. First of all, the majority of included studies provided original data toward Caucasian population, which might reduce the representativeness of our findings in other ethnicity or in general population. Next, language limitation in search strategy might miss some potent reports in other languages, thus leading to possible publication bias not detected by Begg funnel plot or Egger test. Then, significant interstudy heterogeneity existed in the meta-analysis which inevitably affected the precision of our results although we adopted the random-effects model to calculate OR. Besides, about a half of included studies are modulated quality by NOS assessment and the high quality studies are relative small. Last but not least, due to the lack of available information, synergies between genetic and environmental factors were not discussed. Overall, the present study indicates that BMP-14 rs143383 polymorphism may be correlated with decreased risk of OA. However, better-designed studies covering more ethnicity groups as well as gene–gene and gene–environment interactions should be carried out to verify our results.
References

[1] March L, Smith EU, Hoy DG, et al. Burden of disability due to musculoskeletal (MSK) disorders. Best Pract Res Clin Rheumatol 2014;28:353–66.
[2] Litwic A, Edwards MH, Dennison EM, et al. Epidemiology and burden of osteoarthritis. Br Med Bull 2013;105:185–99.
[3] Hochberg MC, Yerges-Armstrong L, Yau M, et al. Genetic epidemiology of osteoarthritis: recent developments and future directions. Curr Opin Rheumatol 2015;23:192–7.
[4] Hutton CW. Osteoarthritis: the cause not result of joint failure? Ann Rheum Dis 1989;48:958–61.
[5] Brandt KD, Dieppe P, Radin E. Etiopathogenesis of osteoarthritis. Med Clin North Am 2009;93:1–24. xv.
[6] Glyt-Jones S, Palmer AJ, Agisola R, et al. Osteoarthritis. Lancet 2015;386:376–87.
[7] Peach CA, Carr AJ, Loughlin J. Recent advances in the genetic investigation of osteoarthritis. Trends Mol Med 2005;11:186–91.
[8] Loughlin J. The genetic epidemiology of human primary osteoarthritis: current status. Expert Rev Mol Med 2005;7:1–2.
[9] Spector TD, Cicuttini F, Baker J, et al. Genetic influences on osteoarthritis in women: a twin study. BMJ 1996;312:940–3.
[10] Jiang D, Hao Z, Fan D, et al. Association between GDF5 +104T/C polymorphism and knee osteoarthritis in Caucasian and Asian populations: a meta-analysis based on case-control studies. J Orthop Surg Res 2016;11:104.
[11] McHugh J. Osteoarthritis: GDF5 modiﬁcation disease in OA rat model. Nat Rev Rheumatol 2017;13:3.
[12] Buxton P, Edwards C, Archer CW, et al. Growth/differentiation factor-5 (GDF-5) and skeletal development. J Bone Joint Surg Am 2001;83-A(Suppl 1):S23–30.
[13] Lortjon FP. Cartilage-derived morphogenetic protein-1. Int J Biochem Cell Biol 1997;29:1241–4.
[14] Edwards CJ, Francis-West PH. Bone morphogenetic proteins in the development and healing of synovial joints. Semin Arthritis Rheum 2013;42.
[15] Mikic B. Multiple effects of GDF-5 during skeletal development. Semin Arthritis Rheum 2001;31:33–42.
[16] Mikic B. Multiple effects of GDF-5 deficiency on skeletal tissues: implications for therapeutic bioengineering. Ann Biomed Eng 2004;32:466–76.
[17] Francis-West PH, Abdelfattah A, Chen P, et al. Mechanisms of GDF-5 action during skeletal development. Development 1999;126:1305–15.
[18] Hatakeyama M, Tani R, Shum L. Distinct functions of BMP4 and GDF5 in the regulation of chondrogenesis. J Cell Biochem 2004;91:1204–17.
[19] Nickel J, Kotzsch A, Sebald W, et al. A single residue of GDF5 defines binding speciﬁcity to BMP receptors IB. J Mol Biol 2005;349:933–47.
[20] Tsukami N, Tanaka K, Aikiwa-Hirasawa E, et al. Role of CDMP-1 in skeletal morphogenesis: promotion of mesenchymal cell recruitment and chondrocyte differentiation. J Cell Biol 1999;144:161–73.
[21] Chen H, Capellini TD, Schoor M, et al. Heads, shoulders, elbows, knees, and toes: modular Gdf5 enhancers control different joints in the vertebrate skeleton. PLoS Genet 2016;12:e1006454.
[22] Ratnayake M, Tselepi M, Bloxham R, et al. A consistent and potentially exploitable response during chondrogenesis of mesenchymal stem cells from osteoarthritis patients to the protein encoded by the susceptibility gene GDF5. PLoS One 2017;12:e0176523.
[23] Erlacher I, McCartney J, Piek E, et al. Cartilage-derived morphogenetic proteins and osteogenic protein-1 differentially regulate osteogenesis. J Bone Miner Res 1998;13:383–92.
[24] Miyamoto Y, Mabuchi A, Shi D, et al. A functional polymorphism in the 5′ UTR of GDF5 is associated with susceptibility to osteoarthritis. Nat Genet 2007;39:529–33.
[25] Bijsterbosch J, Klokkenburg M, Reijnierse M, et al. Association study of candidate genes for the progression of hand osteoarthritis. Osteoarthritis Cartilage 2013;21:565–9.
[26] Takahashi H, Nakajima M, Ozaki K, et al. Prediction model for knee osteoarthritis based on genetic and clinical information. Arthritis Res Ther 2010;12:R187.
[27] Mishra A, Sanghi D, Sharma CA, et al. Association of polymorphism in growth and differentiation factor 5 gene with osteoarthritis knee. Am J Biochem Biotechnol 2013;9:1–7.
[28] Zhang C, Lee HS, Song JH, et al. Growth differentiation factor 5 (GDF5) core promoter polymorphism is not associated with susceptibility to osteoarthritis of the knee in the Korean population. Korean J Pathol 2010;44:404–9.
[29] Chapman K, Takahashi A, Meulenbelt I, et al. A meta-analysis of European and Asian cohorts reveals a global role of a functional SNP in the 5′ UTR of GDF5 with osteoarthritis susceptibility. Hum Mol Genet 2008;17:1497–504.
[30] Southam L, Rodriguez-Lopez J, Wilkins JM, et al. An SNP in the 5′-UTR of GDF5 is associated with osteoarthritis susceptibility in Europeans and with in vivo differences in allelic expression in articular cartilage. Hum Mol Genet 2007;16:2226–32.
[31] Tawonsawawrot T, Changthong T, Pongsuthiwong S, et al. A genetic association study between growth differentiation factor 5 (GDF5) polymorphism and knee osteoarthritis in Thai population. J Orthop Surg Res 2011;6:47.
[32] Tsezou A, Sutro M, Oikonomou P, et al. The growth differentiation factor 5 (GDF5) core promoter polymorphism is not associated with knee osteoarthritis in the Greek population. J Orthop Res 2008;26:136–40.
[33] Shin MH, Lee SJ, Kee SJ, et al. Genetic association analysis of GDF5 and ADAM12 for knee osteoarthritis. Joint Bone Spine 2012;79:488–91.
[34] Evangelou E, Chapman K, Meulenbelt I, et al. Large-scale analysis of association between GDF5 and FRZB variants and osteoarthritis of the hip, knee, and hand. Arthritis Rheum 2009;60:1710–21.
[35] Valdes AM, Spector TD, Doherty M, et al. Association of the DVWA and ADAM12 for knee osteoarthritis. Joint Bone Spine 2012;79:488–91.
[36] Valdes AM, Spector TD, Doherty M, et al. Association of the DVWA and ADAM12 for knee osteoarthritis. Joint Bone Spine 2012;79:488–91.
[37] Vaes RB, Rivadeneira F, Kerkhof JM, et al. Genetic variation in the GDF5 gene is associated with osteoarthritis of the knee with genome-wide statistical significance. Ann Rheum Dis 2011;70:873–5.
[38] Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarth Cartilage 2008;16:137–62.
[39] Hochberg MC, Altman RD, April KT, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res 2012;64:465–74.